Becton, Dickinson and Company (NYSE:BDX) Stock Holdings Lifted by Norway Savings Bank

Norway Savings Bank boosted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 2.5% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,248 shares of the medical instruments supplier’s stock after acquiring an additional 129 shares during the period. Norway Savings Bank’s holdings in Becton, Dickinson and Company were worth $1,202,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Hillsdale Investment Management Inc. lifted its holdings in shares of Becton, Dickinson and Company by 1.7% in the 4th quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier’s stock worth $694,000 after purchasing an additional 50 shares during the last quarter. Alpha Omega Wealth Management LLC lifted its stake in Becton, Dickinson and Company by 5.7% in the first quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier’s stock valued at $225,000 after buying an additional 53 shares during the last quarter. Brady Family Wealth LLC lifted its stake in Becton, Dickinson and Company by 1.2% in the first quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier’s stock valued at $989,000 after buying an additional 53 shares during the last quarter. Picton Mahoney Asset Management lifted its stake in Becton, Dickinson and Company by 61.4% in the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 54 shares during the last quarter. Finally, REAP Financial Group LLC lifted its position in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 55 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.0%

BDX opened at $168.58 on Friday. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.64 and a current ratio of 1.13. The stock’s fifty day moving average is $179.58 and its 200-day moving average is $211.27. The company has a market capitalization of $48.32 billion, a PE ratio of 32.17, a P/E/G ratio of 1.27 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The firm had revenue of $5.27 billion for the quarter, compared to analysts’ expectations of $5.35 billion. During the same period in the previous year, the business earned $3.17 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 4.5% compared to the same quarter last year. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be issued a $1.04 dividend. The ex-dividend date is Monday, June 9th. This represents a $4.16 annualized dividend and a dividend yield of 2.47%. Becton, Dickinson and Company’s dividend payout ratio is currently 79.39%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the business’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the sale, the executive vice president now owns 4,575 shares in the company, valued at approximately $783,194.25. The trade was a 20.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 479 shares of the business’s stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the sale, the executive vice president now owns 4,887 shares in the company, valued at $964,107.36. This represents a 8.93% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Raymond James Financial downgraded shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Friday, May 2nd. Stifel Nicolaus cut their price target on Becton, Dickinson and Company from $280.00 to $224.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. William Blair downgraded Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 1st. Citigroup downgraded Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and cut their target price for the company from $217.00 to $185.00 in a research note on Thursday, May 22nd. Finally, Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Friday, May 2nd. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $219.22.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.